Literature DB >> 23766362

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter.

Lorenza Rimassa, Jordi Bruix, Massimo Broggini, Armando Santoro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23766362     DOI： 10.1158/1078-0432.CCR-13-1321

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  6 in total

Review 1.  Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial.

Authors:  Lorenza Rimassa; Camillo Porta; Ivan Borbath; Bruno Daniele; Richard S Finn; Jean-Luc Raoul; Lawrence H Schwartz; Aiwu Ruth He; Joerg Trojan; Markus Peck-Radosavljevic; Giovanni Abbadessa; Terri Goldberg; Armando Santoro; Jordi Bruix
Journal:  Hepat Oncol       Date:  2014-01-29

Review 2.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

Review 3.  Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review.

Authors:  Florian P Reiter; Najib Ben Khaled; Liangtao Ye; Changhua Zhang; Max Seidensticker; Mark Op den Winkel; Gerald Denk; Andreas Geier; Enrico N De Toni
Journal:  Dig Dis       Date:  2021-10-13       Impact factor: 3.421

4.  Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer.

Authors:  Pierre Saintigny; William N William; Jean-Philippe Foy; Vassiliki Papadimitrakopoulou; Wenhua Lang; Li Zhang; You Hong Fan; Lei Feng; Edward S Kim; Adel K El-Naggar; J Jack Lee; Li Mao; Waun Ki Hong; Mark W Lingen; Scott M Lippman
Journal:  J Natl Cancer Inst       Date:  2018-03-01       Impact factor: 11.816

5.  Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1.

Authors:  Shuai Lu; Helga-Paula Török; Eike Gallmeier; Frank T Kolligs; Antonia Rizzani; Sabrina Arena; Burkhard Göke; Alexander L Gerbes; Enrico N De Toni
Journal:  Oncotarget       Date:  2015-09-08

6.  Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.

Authors:  Lorenza Rimassa; Giovanni Abbadessa; Nicola Personeni; Camillo Porta; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean-Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Enrico N De Toni; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Maria E Lamar; Yunxia Wang; Dale Shuster; Brian E Schwartz; Armando Santoro
Journal:  Oncotarget       Date:  2016-11-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.